<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7445120\results\search\disease\results.xml">
  <result pre=": bold;} span.year {font-family : courier ; font-style : italic;}" exact="Diabetes" post="Res Clin PractDiabetes Res. Clin. PractDiabetes Research and Clinical"/>
  <result pre="B.V. pmcid: 7445120S0168-8227(20)30639-2 doi: 10.1016/j.diabres.2020.108386108386 : Article The association of" exact="diabetes" post="and the prognosis of COVID-19 patients: A retrospective study"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="COVID-19 were enrolled from Tongji Hospital (Wuhan, China). Patients without" exact="diabetes" post="were matched to those with diabetes based on age,"/>
  <result pre="(Wuhan, China). Patients without diabetes were matched to those with" exact="diabetes" post="based on age, sex, and comorbidities. All patients were"/>
  <result pre="from medical records and analyzed. Results 64 patients with pre-existing" exact="diabetes" post="were included in this study, with 128 matched patients"/>
  <result pre="were included in this study, with 128 matched patients without" exact="diabetes" post="included as a control group. Patients with diabetes had"/>
  <result pre="patients without diabetes included as a control group. Patients with" exact="diabetes" post="had a higher rate of worsening (18.8% versus 7.8%,"/>
  <result pre="with a higher risk of worsening. Conclusions COVID-19 patients with" exact="diabetes" post="had a higher risk of worsening, especially those with"/>
  <result pre="in patients with diabetes. Keywords Antidiabetic drugs Antihypertensive drugs COVID-19" exact="Diabetes" post="HbA1c Abbreviations ACE-2, Angiotensin-converting enzyme 2 ACEI, Angiotensin-converting enzyme"/>
  <result pre="Angiotensin-converting enzyme inhibitor ARB, Angiotensin II receptor 1 blocker BG," exact="Blood" post="glucose CCB, Calcium channel blocker cTnI, Cardiac troponin I"/>
  <result pre="1 blocker BG, Blood glucose CCB, Calcium channel blocker cTnI," exact="Cardiac" post="troponin I CRP, C-reactive protein DM, Diabetes mellitus HbA1c,"/>
  <result pre="channel blocker cTnI, Cardiac troponin I CRP, C-reactive protein DM," exact="Diabetes mellitus" post="HbA1c, Glycated hemoglobin A1c ICU, Intensive care unit COVID-19,"/>
  <result pre="Glycated hemoglobin A1c ICU, Intensive care unit COVID-19, Novel coronavirus" exact="disease" post="2019 NT-proBNP, N-terminal brain natriuretic peptide precursor SARS-CoV-2, Severe"/>
  <result pre="Intensive care unit COVID-19, Novel coronavirus disease 2019 NT-proBNP, N-terminal" exact="brain" post="natriuretic peptide precursor SARS-CoV-2, Severe acute respiratory syndrome coronavirus"/>
  <result pre="coronavirus disease 2019 NT-proBNP, N-terminal brain natriuretic peptide precursor SARS-CoV-2," exact="Severe" post="acute respiratory syndrome coronavirus 2 1 Introduction Since Dec"/>
  <result pre="disease 2019 NT-proBNP, N-terminal brain natriuretic peptide precursor SARS-CoV-2, Severe" exact="acute" post="respiratory syndrome coronavirus 2 1 Introduction Since Dec 2019,"/>
  <result pre="2019 NT-proBNP, N-terminal brain natriuretic peptide precursor SARS-CoV-2, Severe acute" exact="respiratory" post="syndrome coronavirus 2 1 Introduction Since Dec 2019, the"/>
  <result pre="NT-proBNP, N-terminal brain natriuretic peptide precursor SARS-CoV-2, Severe acute respiratory" exact="syndrome" post="coronavirus 2 1 Introduction Since Dec 2019, the novel"/>
  <result pre="coronavirus 2 1 Introduction Since Dec 2019, the novel coronavirus" exact="disease" post="2019 (COVID-19) has spread rapidly around the world and"/>
  <result pre="The pathogen was identified as a novel, highly contagious severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), which can invade the"/>
  <result pre="pathogen was identified as a novel, highly contagious severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), which can invade the human"/>
  <result pre="was identified as a novel, highly contagious severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), which can invade the human body"/>
  <result pre="myalgia, fatigue etc, and severe cases can rapidly develop into" exact="acute" post="respiratory distress syndrome, septic shock, and multiple organ dysfunction"/>
  <result pre="fatigue etc, and severe cases can rapidly develop into acute" exact="respiratory" post="distress syndrome, septic shock, and multiple organ dysfunction syndrome"/>
  <result pre="severe cases can rapidly develop into acute respiratory distress syndrome," exact="septic shock," post="and multiple organ dysfunction syndrome [3]. Recent studies have"/>
  <result pre="acute respiratory distress syndrome, septic shock, and multiple organ dysfunction" exact="syndrome" post="[3]. Recent studies have shown that diabetes mellitus (DM)"/>
  <result pre="multiple organ dysfunction syndrome [3]. Recent studies have shown that" exact="diabetes mellitus" post="(DM) is one of the most common comorbidities of"/>
  <result pre="a prevalence ranging from 5.3% to 58.0% [4], [5], [6]." exact="Diabetes" post="has been associated with an increased mortality in previous"/>
  <result pre="Diabetes has been associated with an increased mortality in previous" exact="viral" post="epidemics, such as the outbreak of SARS-CoV-1 and Middle"/>
  <result pre="epidemics, such as the outbreak of SARS-CoV-1 and Middle East" exact="respiratory" post="syndrome coronavirus [7], [8]. Similar conclusions were reported in"/>
  <result pre="such as the outbreak of SARS-CoV-1 and Middle East respiratory" exact="syndrome" post="coronavirus [7], [8]. Similar conclusions were reported in the"/>
  <result pre="in the pandemic of SARS-CoV-2. Some studies have suggested that" exact="diabetes" post="is a risk factor for the poor prognosis of"/>
  <result pre="[4], [9], [10], while some studies reported that patients with" exact="diabetes" post="seemed not to have a higher mortality risk [11],"/>
  <result pre="higher mortality risk [11], [12]. Data regarding the impact of" exact="diabetes" post="on the prognosis of COVID-19 patients are scant and"/>
  <result pre="glycemic control should be the most important for patients with" exact="diabetes" post="during the COVID-19 infection as it has been shown"/>
  <result pre="the most important for patients with diabetes during the COVID-19" exact="infection" post="as it has been shown to improve the innate"/>
  <result pre="improve the innate immune system [13], [14]. Data from other" exact="viral" post="epidemics such as SARS and influenza H1N1 has demonstrated"/>
  <result pre="also have been considered as a link between COVID-19 and" exact="diabetes" post="because they are widely used in patients with diabetes"/>
  <result pre="and diabetes because they are widely used in patients with" exact="diabetes" post="[18]. However, there are still no solid evidences demonstrating"/>
  <result pre="we aimed to evaluate the prognosis of COVID-19 patients with" exact="diabetes" post="and the impact of previous glycemic control on it."/>
  <result pre="antidiabetic and antihypertensive drugs on the prognosis of patients with" exact="diabetes" post="was also explored. 2 Methods 2.1 Study design and"/>
  <result pre="admitted from February 3, 2020 to February 26, 2020. SARS-CoV-2" exact="infection" post="was confirmed in all patients based on reverse transcription-polymerase"/>
  <result pre="chain reaction according to the criteria of the New Coronavirus" exact="Pneumonia" post="Prevention and Control Program (5th edition) published by the"/>
  <result pre="by the National Health Commission of China [19]. Patients with" exact="diabetes" post="were designated according to the patientâ€™s medical history. Then"/>
  <result pre="according to the patientâ€™s medical history. Then the patients without" exact="diabetes" post="were matched (2:1 ratio) to the patients with diabetes"/>
  <result pre="without diabetes were matched (2:1 ratio) to the patients with" exact="diabetes" post="based on age, sex, and comorbidities (hypertension, hyperlipemia, chronic"/>
  <result pre="with diabetes based on age, sex, and comorbidities (hypertension, hyperlipemia," exact="chronic" post="renal diseases). The study was approved by the Ethics"/>
  <result pre="aspartate aminotransferase, Î³-glutamyl transferase, creatinine, C-reactive protein (CRP), D-dimer, N-terminal" exact="brain" post="natriuretic peptide precursor (NT-proBNP), cardiac troponin I (cTnI), prothrombin"/>
  <result pre="natriuretic peptide precursor (NT-proBNP), cardiac troponin I (cTnI), prothrombin time," exact="total" post="cholesterol, triglyceride, interleukin-6, tumor necrosis factor-Î±. Model 2 included"/>
  <result pre="cardiac troponin I (cTnI), prothrombin time, total cholesterol, triglyceride, interleukin-6," exact="tumor" post="necrosis factor-Î±. Model 2 included HbA1c and the maximum"/>
  <result pre="antidiabetic or antihypertensive drug and the outcomes, due to the" exact="limited" post="number of patients in each subset, logistic regression model"/>
  <result pre="two-sided P valueÂ 3 Results 3.1 Demographics and characteristics A" exact="total" post="of 64 confirmed COVID-19 patients with pre-existing DM were"/>
  <result pre="in this study (Table 1 ). 128 COVID-19 patients without" exact="diabetes" post="were included as a control group, closely matched for"/>
  <result pre="sex and comorbidities. The median age of the patients with" exact="diabetes" post="was 66.0Â years (IQR, 59.0â€&quot;71.0), and 35 (54.7%) were"/>
  <result pre="59.0â€&quot;71.0), and 35 (54.7%) were male. 39 (60.9%) patients with" exact="diabetes" post="had at least one other comorbidities, with hypertension (37"/>
  <result pre="patients with diabetes had at least one other comorbidities, with" exact="hypertension" post="(37 [57.8%]) being the most common comorbidity. The median"/>
  <result pre="to admission was 10.0Â days (IQR, 7.0â€&quot;15.0) for patients with" exact="diabetes" post="and 14.0Â days (IQR, 8.0â€&quot;17.0) for patients without diabetes."/>
  <result pre="both groups were fever and cough, followed by fatigue and" exact="diarrhea" post="(Table 1). The patients with diabetes reported a significantly"/>
  <result pre="followed by fatigue and diarrhea (Table 1). The patients with" exact="diabetes" post="reported a significantly higher incidence of fever (76.6% versus"/>
  <result pre="66 (59.0â€&quot;71.0) 0.998 Male gender 69 (53.9%) 35 (54.7%) 0.830" exact="Female" post="gender 59 (46.1%) 29 (45.3%) â€&quot;â€&quot; Comorbidities on Admission"/>
  <result pre="(45.3%) â€&quot;â€&quot; Comorbidities on Admission 79 (61.7%) 39 (60.9%) 0.916" exact="Hypertension" post="76 (59.4%) 37 (57.8%) 0.836 Hyperlipemia 9 (7.0%) 5"/>
  <result pre="(61.7%) 39 (60.9%) 0.916 Hypertension 76 (59.4%) 37 (57.8%) 0.836" exact="Hyperlipemia" post="9 (7.0%) 5 (7.8%) 1.000 Chronic renal diseases 1"/>
  <result pre="(59.4%) 37 (57.8%) 0.836 Hyperlipemia 9 (7.0%) 5 (7.8%) 1.000" exact="Chronic" post="renal diseases 1 (0.8%) 0 (0.0%) 1.000 Smoking status"/>
  <result pre="Former/current 19 (14.8%) 8 (12.5%) â€&quot;â€&quot; Clinical characteristics on admission" exact="Systolic" post="pressure, mmHg 132.0 (119.5â€&quot;145.0) 133.5 (120.0â€&quot;145.8) 0.695 Diastolic pressure,"/>
  <result pre="on admission Systolic pressure, mmHg 132.0 (119.5â€&quot;145.0) 133.5 (120.0â€&quot;145.8) 0.695" exact="Diastolic" post="pressure, mmHg 78.0 (70.0â€&quot;86.5) 78.5 (70.0â€&quot;87.8) 0.873 Pulse oxygen"/>
  <result pre="from onset to admission, days 14.0 (8.0â€&quot;17.0) 10.0 (7.0â€&quot;15.0) 0.145" exact="Fever" post="79 (61.7%) 49 (76.6%) 0.040 Highest temperature, â&quot;ƒ 38.3"/>
  <result pre="(0.0%) 0 (0.0%) â€&quot;â€&quot; Myalgia 16 (12.5%) 6 (9.4%) 0.522" exact="Diarrhea" post="21 (16.4%) 11 (17.2%) 0.891 Data are presented as"/>
  <result pre="groups are summarized in Table 2 . The rate of" exact="disease" post="worsening during hospitalization was significantly higher in the patients"/>
  <result pre="the patients with pre-existing DM compared to the patients without" exact="diabetes" post="(18.8% versus 7.8%, pÂ =Â 0.025). Compared to the"/>
  <result pre="=Â 0.025). Compared to the group without diabetes, patients with" exact="diabetes" post="presented higher BG level as expected (8.6Â mmol/L [6.5â€&quot;15.6]"/>
  <result pre="were significantly higher in patients with diabetes. Moreover, patients with" exact="diabetes" post="demonstrated a significantly higher incidence of lymphopenia (53.1% versus"/>
  <result pre="Moreover, patients with diabetes demonstrated a significantly higher incidence of" exact="lymphopenia" post="(53.1% versus 33.6%). As for the inflammatory markers, the"/>
  <result pre="the CRP level was significantly higher in the group with" exact="diabetes" post="(39.3Â mg/L [2.9â€&quot;72.3] versus 7.6Â mg/L [1.6â€&quot;31.6]) while the"/>
  <result pre="showed no difference between the two groups. Besides, patients with" exact="diabetes" post="showed a higher level of the NT-proBNP. Table 2"/>
  <result pre="8.3 (6.6â€&quot;10.2) 0.002 Hemoglobin, g/L 125.5 (116.0â€&quot;135.0) 128.0 (115.0â€&quot;138.0) 0.257" exact="Platelet" post="count, Ã— 109/L 258.0 (181.5â€&quot;332.0) 237.0 (188.0â€&quot;323.0) 0.849 Alanine"/>
  <result pre="(57.3â€&quot;84.0) 0.614 Î³-glutamyl transferase, U/L 23.5 (16.0â€&quot;37.5) 27.0 (17.3â€&quot;64.0) 0.089" exact="Total" post="bilirubin, mmol/L 7.8 (5.8â€&quot;11.1) 8.0 (5.9â€&quot;11.8) 0.522 Creatinine, Î¼mol/L"/>
  <result pre="&amp;lt;0.001 Prothrombin time, second 13.5 (13.0â€&quot;14.2) 13.7 (13.0â€&quot;14.3) 0.615 Activated" exact="partial" post="thromboplastin time, second 38.2 (35.8â€&quot;42.2) 38.5 (34.6â€&quot;44.1) 0.836 D-dimer,"/>
  <result pre="(34.6â€&quot;44.1) 0.836 D-dimer, mg/L 0.7 (0.3â€&quot;1.5) 0.8 (0.4â€&quot;1.7) 0.422 N-terminal" exact="brain" post="natriuretic peptide precursor, pg/mL 113.5 (59.3â€&quot;300.0) 194.5 (87.8â€&quot;423.0) 0.032"/>
  <result pre="brain natriuretic peptide precursor, pg/mL 113.5 (59.3â€&quot;300.0) 194.5 (87.8â€&quot;423.0) 0.032" exact="Cardiac" post="troponin I, ng/mL 4.3 (2.3â€&quot;9.3) 4.9 (2.2â€&quot;17.4) 0.457 Interleukin-6,"/>
  <result pre="4.9 (2.2â€&quot;17.4) 0.457 Interleukin-6, pg/mL 4.5 (2.3â€&quot;15.8) 6.5 (1.8â€&quot;27.3) 0.451" exact="Tumor" post="necrosis factor-Î±, pg/mL 8.0 (6.0â€&quot;10.7) 7.8 (6.1â€&quot;10.6) 0.740 ICU"/>
  <result pre="between glycemic control and the outcomes of the patients with" exact="diabetes" post="Complete data collected from 64 patients with diabetes (12"/>
  <result pre="glycemic control and the outcomes of the patients with diabetes" exact="Complete" post="data collected from 64 patients with diabetes (12 in"/>
  <result pre="patients with diabetes Complete data collected from 64 patients with" exact="diabetes" post="(12 in the worsening group, and 52 in the"/>
  <result pre="of the association between glycemic control and the risk of" exact="disease" post="worsening. Model 1a Model 2b Model 3c Parameters OR"/>
  <result pre="cmultivariate analysis included the variables with a P valueÂ Using" exact="disease" post="worsening as the end point, ROC curve analysis was"/>
  <result pre="count and the percentage of neutrophils. Also, the incidence of" exact="lymphopenia" post="was higher in the poorly-controlled patients. Levels of the"/>
  <result pre="Table 4 Demographics and clinical characteristics of COVID-19 patients with" exact="diabetes" post="in the well-controlled and poorly-controlled HbA1c groups. Parameters HbA1cÂ"/>
  <result pre="67.0 (58.5â€&quot;75.0) 0.535 Male gender 21 (48.8%) 15 (71.4%) 0.073" exact="Female" post="gender 22 (51.2%) 6 (28.6%) â€&quot;â€&quot; Comorbidities on Admission"/>
  <result pre="Female gender 22 (51.2%) 6 (28.6%) â€&quot;â€&quot; Comorbidities on Admission" exact="Hypertension" post="28 (65.1%) 9 (42.9%) 0.090 Hyperlipemia 4 (9.3%) 1"/>
  <result pre="â€&quot;â€&quot; Comorbidities on Admission Hypertension 28 (65.1%) 9 (42.9%) 0.090" exact="Hyperlipemia" post="4 (9.3%) 1 (4.8%) 1.000 Chronic renal diseases 0"/>
  <result pre="(65.1%) 9 (42.9%) 0.090 Hyperlipemia 4 (9.3%) 1 (4.8%) 1.000" exact="Chronic" post="renal diseases 0 (0.0%) 0 (0.0%) â€&quot;â€&quot; White cell"/>
  <result pre="7.1 (3.4â€&quot;8.8) 0.030 Hemoglobin, g/L 126.0 (112.0â€&quot;134.0) 137.0 (126.5â€&quot;145.0) 0.005" exact="Platelet" post="count, Ã— 109/L 237.0 (196.0â€&quot;340.0) 214.5 (166.3â€&quot;312.5) 0.305 Alanine"/>
  <result pre="(16.0â€&quot;39.5) 0.582 Aspartate aminotransferase, U/L 25.0 (16.0â€&quot;33.0) 30.0 (20.5â€&quot;37.0) 0.331" exact="Total" post="bilirubin, mmol/L 7.9 (5.7â€&quot;10.3) 8.6 (6.1â€&quot;17.7) 0.131 Alkaline phosphatase,"/>
  <result pre="(58.0â€&quot;85.5) 0.602 Î³-glutamyl transferase, U/L 27.0 (16.0â€&quot;66.0) 28.0 (19.0â€&quot;65.5) 0.932" exact="Total" post="cholesterol, mmol/L 3.7 (3.2â€&quot;4.3) 3.8 (3.1â€&quot;5.0) 0.516 Triglyceride, mmol/L"/>
  <result pre="0.002 Prothrombin time, second 13.4 (12.8â€&quot;14.0) 13.9 (13.4â€&quot;15.5) 0.015 Activated" exact="partial" post="thromboplastin time, second 38.2 (34.3â€&quot;41.9) 40.3 (35.3â€&quot;48.0) 0.153 D-dimer,"/>
  <result pre="(35.3â€&quot;48.0) 0.153 D-dimer, mg/L 0.7 (0.4â€&quot;1.6) 1.2 (0.6â€&quot;2.2) 0.217 N-terminal" exact="brain" post="natriuretic peptide precursor, pg/mL 166.5 (82.0â€&quot;396.8) 388.5 (97.0â€&quot;983.5) 0.230"/>
  <result pre="brain natriuretic peptide precursor, pg/mL 166.5 (82.0â€&quot;396.8) 388.5 (97.0â€&quot;983.5) 0.230" exact="Cardiac" post="troponin I, ng/mL 3.8 (1.9â€&quot;7.6) 13.8 (3.0â€&quot;36.8) 0.011 Interleukin-6,"/>
  <result pre="13.8 (3.0â€&quot;36.8) 0.011 Interleukin-6, pg/mL 4.8 (1.6â€&quot;27.5) 12.0 (2.3â€&quot;24.3) 0.605" exact="Tumor" post="necrosis factor-Î±, pg/mL 7.3 (4.5â€&quot;10.0) 8.9 (6.9â€&quot;10.9) 0.083 ICU"/>
  <result pre="therapy. The association between the use of antidiabetic/antihypertensive drugs and" exact="disease" post="worsening was shown in Supplementary Table 1. Drugs with"/>
  <result pre="and CCBs use were significantly associated with decreased odds of" exact="disease" post="worsening. After adjusting for glucose, HbA1c at admission and"/>
  <result pre="associations between the use of metformin, insulin, ACEIs/ARBs, statins and" exact="disease" post="worsening. 4 Discussion This retrospective cohort study have 3"/>
  <result pre="COVID-19 patients with pre-existing DM had an increased risk of" exact="disease" post="worsening, but poor previous glycemic control, which was reflected"/>
  <result pre="was reflected by HbA1c, was associated with higher odds of" exact="disease" post="worsening. Second, to our knowledge, this was the first"/>
  <result pre="inhibitors and CCBs use were associated with reduced odds of" exact="disease" post="worsening. Metformin, insulin, ACEIs/ARBs and statins were not associated"/>
  <result pre="has been reported. The majority of the studies demonstrated that" exact="diabetes" post="was an important risk factor for the progression or"/>
  <result pre="[4], [9], [10], while some reported that COVID-19 patients with" exact="diabetes" post="seemed not to have a higher mortality risk [11],"/>
  <result pre="recent meta-analysis involving 4 studies suggested that COVID-19 patients with" exact="diabetes" post="had an increased risk of ICU admission and mortality"/>
  <result pre="study. It is worth noting that the judgement of pre-existing" exact="diabetes" post="was based on the patientâ€™s self-report at admission, which"/>
  <result pre="self-report at admission, which could lead to the underdiagnosis of" exact="diabetes" post="in the control group. In fact, the median level"/>
  <result pre="the control group was 6.3%, which was above the normal" exact="upper" post="limit of HbA1c (6.0%). Thus, although our results showed"/>
  <result pre="(6.0%). Thus, although our results showed an increased risk of" exact="disease" post="worsening in COVID-19 patients with diabetes, the risk might"/>
  <result pre="HbA1c control were more susceptible to infections, such as the" exact="infections" post="of Chlamydia pneumoniae, hemolytic streptococci groups B, G, Klebsiella"/>
  <result pre="patients with well HbA1c control [22], [23], [24], [25]. Besides," exact="chronic" post="hyperglycemia was thought to downregulate ACE-2 expression, making cells"/>
  <result pre="with well HbA1c control [22], [23], [24], [25]. Besides, chronic" exact="hyperglycemia" post="was thought to downregulate ACE-2 expression, making cells susceptible"/>
  <result pre="between HbA1c level and the prognosis of COVID-19 patients with" exact="diabetes" post="has not been explored. Our study found that among"/>
  <result pre="those with poor HbA1c control had a higher risk of" exact="disease" post="worsening, with an optimal cut-off value of 8.6% (70Â"/>
  <result pre="group. The HbA1c poorly-controlled patients presented a higher incidence of" exact="lymphopenia" post="(71.4% versus 44.2%) compared to the well-controlled patients. Also,"/>
  <result pre="previously [4], [11], [27], suggesting that the higher risk of" exact="disease" post="worsening in the poorly-controlled group might be associated with"/>
  <result pre="antidiabetic/antihypertensive drugs and the prognosis of the COVID-19 patients with" exact="diabetes" post="was also explored in this study for the first"/>
  <result pre="that Î±-glucosidase inhibitors and CCBs use were associated with a" exact="lower" post="risk of disease worsening, and no significant associations were"/>
  <result pre="and CCBs use were associated with a lower risk of" exact="disease" post="worsening, and no significant associations were observed between the"/>
  <result pre="observed between the use of metformin, insulin, ACEIs/ARBs, statins and" exact="disease" post="worsening after adjusting for glucose, HbA1c at admission and"/>
  <result pre="also recommended on the use of metformin due to the" exact="lactic acidosis" post="associated with it [26]. In addition, previous studies reported"/>
  <result pre="recommended on the use of metformin due to the lactic" exact="acidosis" post="associated with it [26]. In addition, previous studies reported"/>
  <result pre="insulin, Î±-glucosidase inhibitors, ACEIs/ARBs, CCBs, statins and increased odds of" exact="disease" post="worsening. Even the use of Î±-glucosidase inhibitors and CCBs"/>
  <result pre="inhibitors and CCBs were significantly associated with decreased odds of" exact="disease" post="worsening. Although the potential bias of reverse causation cannot"/>
  <result pre="these drugs were not associated with a higher risk of" exact="disease" post="worsening. However, considering the risk of acute metabolic decompensation"/>
  <result pre="higher risk of disease worsening. However, considering the risk of" exact="acute" post="metabolic decompensation caused by metformin in COVID-19 patients with"/>
  <result pre="our study. First, the interpretation of our results might be" exact="limited" post="by the sample size. Second, owing to the retrospective"/>
  <result pre="data didnâ€™t allow us to analyze the type of DM," exact="disease" post="course and mean in-hospital BG. Third, due to the"/>
  <result pre="COVID-19 patients with pre-existing DM had an increased risk of" exact="disease" post="worsening, especially those with poorly-controlled HbA1c, with an optimal"/>
  <result pre="antidiabetic/antihypertensive drugs were not associated with a higher risk of" exact="disease" post="worsening in COVID-19 patients with diabetes. 6 Ethics approval"/>
  <result pre="work reported in this paper. References References 1Organization, W.H.: Coronavirus" exact="disease" post="(COVID-19) Situation dashboard. https://who.sprinklr.com/ (2020). Accessed 2 July 2020"/>
  <result pre="July 2020 2WuZ.McGooganJ.M.Characteristics of and Important Lessons From the Coronavirus" exact="Disease" post="2019 (COVID-19) Outbreak in China: Summary of a Report"/>
  <result pre="Report of 72 314 Cases From the Chinese Center for" exact="Disease" post="Control and PreventionJAMA202010.1001/jama.2020.2648 3ChenN.ZhouM.DongX.QuJ.GongF.HanY.Epidemiological and clinical characteristics of 99"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet (London, England)39510223202050751310.1016/s0140-6736(20)30211-7 4ZhouF.YuT.DuR.FanG.LiuY.LiuZ.Clinical"/>
  <result pre="(London, England)39510223202050751310.1016/s0140-6736(20)30211-7 4ZhouF.YuT.DuR.FanG.LiuY.LiuZ.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="prognosis and practical considerationsDiabet Metabolic Syndrome144202030331010.1016/j.dsx.2020.04.004 7YangJ.K.FengY.YuanM.Y.YuanS.Y.FuH.J.WuB.Y.Plasma glucose levels and" exact="diabetes" post="are independent predictors for mortality and morbidity in patients"/>
  <result pre="patients with SARSDiabet Med J British Diabet Assoc236200662362810.1111/j.1464-5491.2006.01861.x 8Al-TawfiqJ.A.HinediK.GhandourJ.KhairallaH.MuslehS.UjayliA.Middle East" exact="respiratory" post="syndrome coronavirus: a case-control study of hospitalized patientsClin Infect"/>
  <result pre="with SARSDiabet Med J British Diabet Assoc236200662362810.1111/j.1464-5491.2006.01861.x 8Al-TawfiqJ.A.HinediK.GhandourJ.KhairallaH.MuslehS.UjayliA.Middle East respiratory" exact="syndrome" post="coronavirus: a case-control study of hospitalized patientsClin Infect Dis"/>
  <result pre="Du, K., Zhao, L., Fan, H., Luo, S., Hu, D.:" exact="Diabetes" post="is a risk factor for the progression and prognosis"/>
  <result pre="reviews, e3319 (2020). doi:10.1002/dmrr.3319 10HuangR.ZhuL.XueL.LiuL.YanX.WangJ.Clinical findings of patients with coronavirus" exact="disease" post="2019 in Jiangsu province, China: A retrospective, multi-center studyPLoS"/>
  <result pre="A retrospective, multi-center studyPLoS NeglTrop Dis1452020e000828010.1371/journal.pntd.0008280 11WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.Risk Factors Associated With" exact="Acute" post="Respiratory Distress Syndrome and Death in Patients With Coronavirus"/>
  <result pre="retrospective, multi-center studyPLoS NeglTrop Dis1452020e000828010.1371/journal.pntd.0008280 11WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.Risk Factors Associated With Acute" exact="Respiratory" post="Distress Syndrome and Death in Patients With Coronavirus Disease"/>
  <result pre="studyPLoS NeglTrop Dis1452020e000828010.1371/journal.pntd.0008280 11WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.Risk Factors Associated With Acute Respiratory Distress" exact="Syndrome" post="and Death in Patients With Coronavirus Disease 2019 Pneumonia"/>
  <result pre="Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus" exact="Disease" post="2019 Pneumonia in Wuhan ChinaJAMA Internal Med202010.1001/jamainternmed.2020.0994 12YangX.YuY.XuJ.ShuH.XiaJ.LiuH.Clinical course"/>
  <result pre="Distress Syndrome and Death in Patients With Coronavirus Disease 2019" exact="Pneumonia" post="in Wuhan ChinaJAMA Internal Med202010.1001/jamainternmed.2020.0994 12YangX.YuY.XuJ.ShuH.XiaJ.LiuH.Clinical course and outcomes"/>
  <result pre="12YangX.YuY.XuJ.ShuH.XiaJ.LiuH.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respirat"/>
  <result pre="Wuhan, China: a single-centered, retrospective, observational studyLancet Respirat Med85202047548110.1016/s2213-2600(20)30079-5 13PalR.BhansaliA.COVID-19," exact="diabetes mellitus" post="and ACE2: The conundrumDiabet Res Clin Pract162202010813210.1016/j.diabres.2020.108132 14GuptaR.GhoshA.SinghA.K.MisraA.Clinical considerations"/>
  <result pre="The conundrumDiabet Res Clin Pract162202010813210.1016/j.diabres.2020.108132 14GuptaR.GhoshA.SinghA.K.MisraA.Clinical considerations for patients with" exact="diabetes" post="in times of COVID-19 epidemicDiabet Metabolic Syndrome143202021121210.1016/j.dsx.2020.03.002 15BadawiA.RyooS.G.Prevalence of"/>
  <result pre="diabetes in times of COVID-19 epidemicDiabet Metabolic Syndrome143202021121210.1016/j.dsx.2020.03.002 15BadawiA.RyooS.G.Prevalence of" exact="Diabetes" post="in the 2009 Influenza A (H1N1) and the Middle"/>
  <result pre="COVID-19 epidemicDiabet Metabolic Syndrome143202021121210.1016/j.dsx.2020.03.002 15BadawiA.RyooS.G.Prevalence of Diabetes in the 2009" exact="Influenza A (H1N1)" post="and the Middle East Respiratory Syndrome Coronavirus: A Systematic"/>
  <result pre="in the 2009 Influenza A (H1N1) and the Middle East" exact="Respiratory" post="Syndrome Coronavirus: A Systematic Review and Meta-AnalysisJ Public Health"/>
  <result pre="the 2009 Influenza A (H1N1) and the Middle East Respiratory" exact="Syndrome" post="Coronavirus: A Systematic Review and Meta-AnalysisJ Public Health Res53201673310.4081/jphr.2016.733"/>
  <result pre="A Systematic Review and Meta-AnalysisJ Public Health Res53201673310.4081/jphr.2016.733 16ZhuL.SheZ.G.ChengX.QinJ.J.ZhangX.J.CaiJ.Association of" exact="Blood" post="Glucose Control and Outcomes in Patients with COVID-19 and"/>
  <result pre="Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing" exact="Type 2" post="DiabetesCell Metab316202010681077.e106310.1016/j.cmet.2020.04.021 17ZhangJ.DongJ.MartinM.HeM.GongolB.MarinT.L.AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme"/>
  <result pre="Patients with COVID-19 and Pre-existing Type 2 DiabetesCell Metab316202010681077.e106310.1016/j.cmet.2020.04.021 17ZhangJ.DongJ.MartinM.HeM.GongolB.MarinT.L.AMP-activated" exact="Protein" post="Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates"/>
  <result pre="Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates" exact="Pulmonary" post="HypertensionAm J Respir Crit Care Med1984201850952010.1164/rccm.201712-2570OC 18PalR.BhadadaS.K.Should anti-diabetic medications"/>
  <result pre="amid COVID-19 pandemic?Diabetes Res Clin Pract163202010814610.1016/j.diabres.2020.108146 19China, N.H.C.o.: New coronavirus" exact="pneumonia" post="prevention and control program (5th edition) (in Chinese). (2020)."/>
  <result pre="(2020). Accessed 26 February 2020. http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf. 20RonconL.ZuinM.RigatelliG.ZulianiG.Diabetic patients with COVID-19" exact="infection" post="are at higher risk of ICU admission and poor"/>
  <result pre="admission and poor short-term outcomeJ Clin Virol Off Publicat Pan" exact="American" post="Soc Clin Virol127202010435410.1016/j.jcv.2020.104354 21RowleyK.G.DanielM.O'DeaK.Screening for diabetes in Indigenous populations"/>
  <result pre="Virol Off Publicat Pan American Soc Clin Virol127202010435410.1016/j.jcv.2020.104354 21RowleyK.G.DanielM.O'DeaK.Screening for" exact="diabetes" post="in Indigenous populations using glycated haemoglobin: sensitivity, specificity, post-test"/>
  <result pre="of diseaseDiabet Med J British Diabet Assoc227200583383910.1111/j.1464-5491.2005.01447.x 22RizzoA.PaolilloR.IafuscoD.PriscoF.Romano CarratelliC.Chlamydia pneumoniae" exact="infection" post="in adolescents with type 1 diabetes mellitusJ Med Microbiol61Pt"/>
  <result pre="British Diabet Assoc227200583383910.1111/j.1464-5491.2005.01447.x 22RizzoA.PaolilloR.IafuscoD.PriscoF.Romano CarratelliC.Chlamydia pneumoniae infection in adolescents with" exact="type 1" post="diabetes mellitusJ Med Microbiol61Pt 1120121584159010.1099/jmm.0.048512-0 23ThomsenR.W.RiisA.H.KjeldsenS.SchÃ¸nheyderH.C.Impact of diabetes and"/>
  <result pre="Assoc227200583383910.1111/j.1464-5491.2005.01447.x 22RizzoA.PaolilloR.IafuscoD.PriscoF.Romano CarratelliC.Chlamydia pneumoniae infection in adolescents with type 1" exact="diabetes" post="mellitusJ Med Microbiol61Pt 1120121584159010.1099/jmm.0.048512-0 23ThomsenR.W.RiisA.H.KjeldsenS.SchÃ¸nheyderH.C.Impact of diabetes and poor"/>
  <result pre="with type 1 diabetes mellitusJ Med Microbiol61Pt 1120121584159010.1099/jmm.0.048512-0 23ThomsenR.W.RiisA.H.KjeldsenS.SchÃ¸nheyderH.C.Impact of" exact="diabetes" post="and poor glycaemic control on risk of bacteraemia with"/>
  <result pre="polysaccharide biosynthesis and opsonophagocytosis of Klebsiella pneumoniae: Implications for invasive" exact="syndrome" post="in patients with diabetes mellitusVirulence77201677077810.1080/21505594.2016.1186315 25XiaL.L.LiS.F.ShaoK.ZhangX.HuangS.The correlation between CT"/>
  <result pre="of Klebsiella pneumoniae: Implications for invasive syndrome in patients with" exact="diabetes" post="mellitusVirulence77201677077810.1080/21505594.2016.1186315 25XiaL.L.LiS.F.ShaoK.ZhangX.HuangS.The correlation between CT features and glycosylated hemoglobin"/>
  <result pre="and glycosylated hemoglobin level in patients with T2DM complicated with" exact="primary" post="pulmonary tuberculosisInfect Drug Resistance11201818719310.2147/idr.S146741 26BornsteinS.R.RubinoF.KhuntiK.MingroneG.HopkinsD.BirkenfeldA.L.Practical recommendations for the management"/>
  <result pre="glycosylated hemoglobin level in patients with T2DM complicated with primary" exact="pulmonary" post="tuberculosisInfect Drug Resistance11201818719310.2147/idr.S146741 26BornsteinS.R.RubinoF.KhuntiK.MingroneG.HopkinsD.BirkenfeldA.L.Practical recommendations for the management of"/>
  <result pre="pulmonary tuberculosisInfect Drug Resistance11201818719310.2147/idr.S146741 26BornsteinS.R.RubinoF.KhuntiK.MingroneG.HopkinsD.BirkenfeldA.L.Practical recommendations for the management of" exact="diabetes" post="in patients with COVID-19Lancet Diabet Endocrinol86202054655010.1016/s2213-8587(20)30152-2 27WanS.XiangY.FangW.ZhengY.LiB.HuY.Clinical features and"/>
  <result pre="and angiotensin receptor blockers may be harmful in patients with" exact="diabetes" post="during COVID-19 pandemicDiabet Metabolic Syndrome144202034935010.1016/j.dsx.2020.04.019 Appendix A Supplementary material"/>
 </snippets>
</snippetsTree>
